Key result
Long-term moderate-intensity oral anticoagulation may prevent recurrent CAD events in high-risk patients.
Why the study?
Oral anticoagulation therapy in patients with coronary artery disease has been controversial despite its long-term use and recent evidence clarifying its role.
Does long-term, moderate-intensity oral anticoagulation prevent recurrent CAD events in patients with coronary artery disease?
Does long-term, moderate-intensity oral anticoagulation prevent recurrent CAD events in patients with coronary artery disease?
Long-term, moderate-intensity oral anticoagulation (INR 2.0-3.0) is a viable option for preventing recurrent cardiovascular events in high-risk patients with coronary artery disease.
May support OAC consideration in high-risk CAD; leaves open need for randomized confirmation.
Oral anticoagulation (OA) has been used to treat patients with coronary artery disease (CAD) for more than 40 years and has been a subject of intense controversy since that time. Seven to 10% of patients with acute myocardial infarction (MI) develop recurrent MI, stroke, or death in the 6 weeks following the index event and approximately 20% after 4 years, despite optimal background therapy with aspirin. Recent large studies and systematic reviews have greatly clarified the role of OA in the modern era. On the weight of the evidence, which is reviewed in detail in this article, long-term, moderate-intensity OA (International Normalized Ratio 2.0 to 3.0) should be considered an option for the prevention of recurrent CAD, particularly in high-risk patients.
No takes yet. Share an insight, caveat, or question.
Hackam et al. (2003) conducted a review in Coronary artery disease. Oral anticoagulation was evaluated. Long-term, moderate-intensity oral anticoagulation (INR 2.0 to 3.0) should be considered an option for the prevention of recurrent coronary artery disease, particularly in high-risk patients.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: